International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction
ATTR-CM was diagnosed in 18% (95% CI: 13.7-22.5) of evaluable patients with HF, LVEF >40%, and risk markers for ATTR-CM, but no previous diagnosis of amyloidosis. Recruitment bias may have contributed to regional variability. NCT04424914.
Authors
- Sergi Yun (ORCID: https://orcid.org/0000-0003-4858-9566)
- Ronnie Wang
- Eve Cariou
- Pablo García‐Pavía (ORCID: https://orcid.org/0000-0002-5470-2257)
- Lisa Anderson (ORCID: https://orcid.org/0000-0001-5059-3551)
- Ben Ebede
- Giovanni O. Palladini (ORCID: https://orcid.org/0000-0001-5994-5138)
- Franca S. Angeli
Institutions
- St George's, University of London (GB)
- Pfizer (United States) (US)
- Universidad Francisco de Vitoria (ES)
- University of Pavia (IT)
- Instituto de Salud Carlos III (ES)
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Hôpital Rangueil (FR)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Amyloid
- Published
- 2024-09-08
- DOI
- https://doi.org/10.1080/13506129.2024.2398446
- Citations
- 9
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.10
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- University of Ottawa
- Prothena
- Keio University
- Novo Nordisk
- Uniwersytet Łódzki